Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 12, 2007

Immtech’s Pneumocystis Pneumonia Drug Licensed by Par in $147M Deal

  • Immtech Pharmaceuticals granted Par Pharmaceutical an exclusive license to commercialize its treatment of pneumocystis pneumonia (PCP) in AIDS patients in the U.S. Pafuramidine maleate is the company’s lead oral drug. 

    The companies may also collaborate on efforts to develop pafuramidine as a preventative therapy for patients at risk of developing PCP, including people living with HIV, cancer, and other immunosuppressive conditions.

    According to the terms of the signed agreement, Immtech received an initial payment of $3 million from Par. An additional $29 million will be paid as pafuramidine advances through ongoing Phase III trials and U.S. regulatory review and approval. Immtech also will receive royalties as well as up to $115 million in sales-based milestones. Immtech retains the right to co-market pafuramidine in the U.S.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.